Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

million for the second quarter of 2008 and $22 million for the first six months of 2008, as compared to $12 million and $22 million recorded in the prior year periods, respectively.

Margins

Generic: Margins in the generic segment for the second quarter of 2008 and the first six months of 2008 were 45% and 47%, respectively, compared to 49% and 47%, respectively, in the prior year periods.

Proprietary: Margins in the proprietary segment for both the second quarter of 2008 and the first six months of 2008 were 69%, down from 78% and 72% in the prior year periods, respectively, principally due to higher product amortization.

Update on R&D Activities

Research and development expenses totaled $81 million for the second quarter of 2008, compared to $66 million in the prior year period. R&D for the first six months of 2008 totaled $145 million, compared to $129 million for the prior year period. The increases reflect greater investment in generic and bio-generic development activities, both in the U.S. and Europe, as well as in proprietary development activities in the United States and the impact of foreign currency exchange.

Generic Products

At June 30, 2008, the Company had approximately 70 Abbreviated New Drug Applications, including tentatively approved applications, pending at the U.S. Food and Drug Administration (FDA) targeting branded pharmaceutical products with an estimated $29 billion in sales. The Company also had approximately 350 product registrations, representing 89 molecules, pending with regulatory bodies in Europe and ROW.

During the second quarter of 2008, the Company received two generic product approvals in the U.S. from the FDA, and approximately 20 approvals, representing 13 molecules, from regulatory bodies in Europe and ROW.

Proprietary Products

The Company currently has an extensive proprietary clinical development program that includes four products in Phase III studies and
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 - Elsevier, a world-leading provider of ... announced the publication of a recent study in ... human blastocysts showing that those with an abnormal chromosomal ... they have developed to blastocysts, thereby classifying the risk ... study the same group has undertaken a retrospective study, ...
(Date:5/17/2013)... , May 17, 2013 ... the most innovative thought leaders of the medical ... Manufacturing East conference and expo, from June 18-20 ...      (Photo: http://photos.prnewswire.com/prnh/20130517/613829 ) , ... to deliver industry professionals practical presentations and implementable ...
(Date:5/17/2013)... 17, 2013 /PRNewswire-iReach/ -- Aridis is pleased to ... Switzerland -based Kenta Biotech to ... antibody (mAb) products, and technologies. This asset portfolio ... treatment of infections by common pathogens including drug ... Pseudomonas aeruginosa , Acinetobacter baumannii ...
(Date:5/17/2013)... May 17, 2013 The paradigm of ... biological systems that can help predict the adverse and ... Sergey Stepaniants, Head of Computational Biology at the Genomics ... tools to ensure high-quality genomics when used as part ... applied to complex data sets to identify key clinical ...
Breaking Biology Technology:Breakthrough for IVF? 2Breakthrough for IVF? 3MedTech Innovate Seminars: New Interactive Learning Forums at 2013 MD&M East 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 2Aridis Pharmaceuticals Announces Acquisition of Monoclonal Antibody Products and Technologies From Kenta Biotech 3
... CellCyte Genetics,Corporation (the "Company") (OTC Bulletin Board: CCYG) ... develop, manufacture and market its patented,line of stem ... is developing stem cell enabling therapeutic products,designed to ... adult stem cells to diseased organs, such as ...
... Expand Versatility of DelSite cGMP Polymer, ... (Pink Sheets: CARN) today announced its wholly-owned,subsidiary, ... rights license agreement with a biotechnology company ... DelSite,s,high-molecular-weight anionic polysaccharide which is produced under ...
... Sept. 19 /Xinhua-PRNewswire/ -- Shanghai Century (Amex:,SHA), a ... Pharmaceutical Co., Ltd (Kelun), China,s largest producer of,intravenous ... financial highlights with respect to the consolidated results ... interest entity,(Kelun Group) for the first half of ...
Cached Biology Technology:CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 2CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 3CellCyte Genetics Corp. Forms Device Division to Develop and Manufacture Stem Cell Cultivation and Replication Products 4Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 2Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 2Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 3Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 4Shanghai Century Acquisition Corporation Announces Sichuan Kelun Pharmaceutical Co Results for the Six Months Ended June 30, 2007 5
(Date:5/16/2013)... MA -- Injectable nanoparticles developed at MIT may ... 1 diabetes to constantly monitor their blood-sugar levels ... were designed to sense glucose levels in the ... of insulin, thereby replacing the function of pancreatic ... Type 1 diabetes. Ultimately, this type of system ...
(Date:5/16/2013)... an ancient extinct creature with ,scissor hand-like, claws in ... his favourite movie star. , The 505 million ... Koo-ten-ee-che-la depp-eye), which is a distant ancestor of lobsters ... for his starring role as Edward Scissorhands - a ... creation, who has scissors for hands. , ...
(Date:5/16/2013)... Cameroon and the manager of San Diego Zoo Global,s ... Whitley award. The Whitley award is an international ... it celebrates the extraordinary achievements of some of the ... was selected for the award due to his efforts ... its wildlife inhabitants., HRH The Princess Royal, the charity,s ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3Actor Johnny Depp immortalized in ancient fossil find 2Cameroon researcher wins prestigious 'Green Oscar' 2Cameroon researcher wins prestigious 'Green Oscar' 3
... and WEST PALM BEACH, Fla. , May ... authentication and endpoint protection solutions and ScriptRx, a leading ... Systems for Emergency Rooms and Urgent Care Centers, today ... into the ScriptRx System. Designed for these busy clinical ...
... A research appearing in Nature , with ... from the Department of Genetics and Microbiology at UAB, ... virulent genes causing infections. The research describes an unprecedented ... of treating and preventing bacterial infections. , Pathogenic ...
... transport through shipping, income from tourism and recreation ... is a challenge that calls for reframing humans as ... of Europe,s leading marine organisations in a new report ... Board-European Science Foundation (ESF), the International Council for the ...
Cached Biology News:ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 2ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 3ScriptRx and DigitalPersona Team Up to Secure Emergency Room and Urgent Care Electronic Medical Records 4Surprising infection inducing mechanism found in bacteria 2Sustainable use of our seas needs an integrated view of humans and nature 2
... peptide derived from the internal region of ... Specific for the internal region of the ... the target band at ~590 kDa. ... media from primary tracheobranchial epithelial cultures and ...
...
Request Info...
Penicillin-Streptomycin liquid...
Biology Products: